Mezigdomide: Clinical Trials

18 trials of Mezigdomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 recruiting, 3 active not recruiting, 2 completed, 2 terminated. 18 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Recruiting 10, Active not recruiting 3, Completed 2, Terminated 2, Withdrawn 1
Phase 28Recruiting 5, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Mezigdomide: new trials by email Literature Review of Mezigdomide trials Research Report on Mezigdomide

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Ziftomenib, Mezigdomide - KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
Phase 1RecruitingMassachusetts General Hospital242026-09-022026-10-08
A Study of Revumenib and Mezigdomide in People With Leukemia
Revumenib, Mezigdomide - Leukemia, Acute Leukemia
Phase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer Center522026-01-162026-10-20
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Talquetamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM)
Phase 1RecruitingMassachusetts General Hospital252025-12-192026-04-13
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma
Phase 1 / Phase 2RecruitingCelgene622025-10-072026-09-02
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Teclistamab, Mezigdomide - Multiple Myeloma
Phase 1RecruitingMemorial Sloan Kettering Cancer Center182025-08-082026-10-13
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma
Phase 1 / Phase 2RecruitingAbbVie6022025-06-302026-10-19
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM)
Phase 1 / Phase 2RecruitingYOUNGIL KOH752024-11-262025-12-03
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography - Multiple Myeloma
Phase 1Active not recruitingCity of Hope Medical Center152024-04-092026-11-09
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
Mezigdomide - Renal Impairment
Phase 1CompletedCelgene262024-03-212025-06-04
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Alnuctamab, Mezigdomide, Dexamethasone - Multiple Myeloma
Phase 1TerminatedCelgene42024-02-272026-04-21
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
BMS-986393, Alnuctamab, Mezigdomide - Multiple Myeloma
Phase 1RecruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company1872024-02-222026-07-16
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 1Active not recruitingAbdullah Khan122023-12-212026-05-13
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Mezigdomide, Ixazomib, Dexamethasone - Relapsed and Refractory Multiple Myeloma
Phase 1 / Phase 2WithdrawnKathleen Dorritie2023-10-022024-11-19
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) - Multiple Myeloma, Myeloma
Phase 1RecruitingK36 Therapeutics, Inc.1652023-02-222026-10-22
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
Mezigdomide - Hepatic Impairment
Phase 1CompletedBristol-Myers Squibb322023-02-202024-02-07
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
CC-92480, Bortezomib, Dexamethasone - Multiple Myeloma
Phase 1 / Phase 2Active not recruitingCelgene4242019-09-302024-11-29
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
CC-92480, Dexamethasone - Multiple Myeloma
Phase 1 / Phase 2TerminatedCelgene2002018-02-062026-02-09
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Selinexor, Dexamethasone, Lenalidomide - Multiple Myeloma
Phase 1 / Phase 2RecruitingKaryopharm Therapeutics Inc3002015-10-012026-07-15

Conditions studied

Multiple Myeloma (14)  ·  Recurrence (5)  ·  Leukemia, Myeloid, Acute (2)  ·  Kidney Failure, Chronic (1)  ·  Leukemia (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Neoplasms (1)  ·  Neoplasms, Plasma Cell (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Renal Insufficiency (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Celgene (5)  ·  Massachusetts General Hospital (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  AbbVie (1)  ·  Abdullah Khan (1)  ·  Bristol-Myers Squibb (1)  ·  City of Hope Medical Center (1)  ·  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1)  ·  K36 Therapeutics, Inc. (1)  ·  Karyopharm Therapeutics Inc (1)  ·  Kathleen Dorritie (1)  ·  YOUNGIL KOH (1)

Countries

United States (16)  ·  Canada (6)  ·  Spain (4)  ·  Greece (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Denmark (2)  ·  France (2)  ·  Germany (2)  ·  Israel (2)  ·  Japan (2)  ·  Norway (2)  ·  South Korea (2)  ·  Belgium (1)  ·  China (1)

Top investigators

Abdullah M Khan, MBBS, MSc (1)  ·  Amir Fathi, MD (1)  ·  Andrew J. Yee, MD (1)  ·  Kathleen A Dorritie, MD (1)  ·  Kuo-Kai Chin, MD (1)  ·  Malin Hultcrantz, MD, PhD (1)  ·  Murali Janakiram (1)

Results publications

PMID 30352784, PMID 37393120, PMID 37646702, PMID 38826786

NIH funding

2023 (2), 2017 (1), 2025 (1), P30CA033572 (1)